Comment from Cureledger, Inc.

Summary: Cureledger, Inc., a life data trust for rare diseases, supports the draft guidance and the Plausible Mechanism Framework for accelerating drug development. They recommend that the final guidance include consolidated data standards for natural history studies, enhanced privacy protections for small populations, and clear protocols for data lifecycle and custody to ensure data persistence.